Teva and China Resources Guangdong Pharmaceutical Forge Strategic Partnership to Enhance Access to Innovative Migraine Treatment in Greater Bay Area

Shanghai, November 6, 2023 /PRNewswire/ -- On November 6, 2023, during the Sixth China International Import Expo, Teva Pharmaceutical Industries Ltd., a global leader in the biopharmaceutical field, and China Resources Guangdong Pharmaceutical Co., Ltd. ("China Resources Guangdong Pharmaceutical"), a leading company in China's pharmaceutical distribution industry, jointly announced the launch of their strategic partnership. Based on the principles of "complementary strengths, long-term cooperation, and mutual benefit," the two parties will leverage their respective advantages to engage in deep collaboration and exploration across multiple areas, including the introduction of Remanezumab (Fremanezumab), an internationally advanced innovative migraine drug in the Guangdong-Hong Kong-Macao Greater Bay Area, logistics and distribution services, supply chain management, and promoting the high-quality implementation of the "Hong Kong-Macao Medicine and Device Access" policy.

Teva and China Resources Guangdong Pharmaceutical Co., Ltd. Sign Strategic Cooperation Agreement to Jointly Enhance Access to Innovative Drugs for the Greater Bay Area Population

On September 29, 2020, eight departments including the State Administration for Market Regulation, the National Medical Products Administration, and the National Development and Reform Commission jointly issued the "Work Plan for Innovation and Development of Pharmaceutical and Medical Device Regulation in the Guangdong-Hong Kong-Macao Greater Bay Area" (referred to as the "Hong Kong-Macao Medicine and Device Link" policy). This policy allows designated medical institutions operating within the nine mainland cities of the Guangdong-Hong Kong-Macao Greater Bay Area to use urgently needed medicines that have already been marketed in Hong Kong and Macao, as well as urgently needed medical devices that have been procured by public hospitals in Hong Kong and Macao and possess clinical application advancement.

Under the promotion of the "Hong Kong-Macao Medicine and Medical Device Access" policy, in July 2023, Teva's innovative drug – Fremanezumab, for the preventive treatment of migraine – received urgent approval for Hong Kong-Macao medical devices in the mainland of the Guangdong-Hong Kong-Macao Greater Bay Area, and was approved by the Guangdong Provincial Drug Administration. China Resources Guangdong Pharmaceutical Co., Ltd. is responsible for the import procurement and distribution. On July 8, the first patient was administered Fremanezumab at Guangzhou United Family Hospital, one of the first pilot medical institutions. This means that patients seeking treatment at designated medical institutions in the mainland of the Guangdong-Hong Kong-Macao Greater Bay Area are now able to use this innovative drug, which has not yet been approved for marketing in China, with the potential to significantly improve their quality of life. Based on this significant cooperative breakthrough, Teva and China Resources Guangdong Pharmaceutical continue to join hands for further in-depth cooperation.

Mr. Huang Diren, General Manager of Teva Greater China

Mr. Huang Diren, General Manager of Teva Greater China, stated: "Teva has long been committed to the research, development, and production of innovative and high-quality medicines, with a particular focus on key disease areas such as the nervous system, aiming to improve patients' quality of life. Since entering the Chinese mainland market, Teva has been dedicated to fulfilling its promise of ‘bringing better medicines to Chinese patients more quickly.’ We focus on addressing patients' most urgent clinical needs, accelerating the introduction of innovative drugs, and contributing to the realization of the ‘Healthy China 2030’ vision. We look forward to working with China Resources Guangdong Pharmaceutical Co., Ltd. to actively explore establishing deep cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area. This collaboration aims to achieve integrated development across the entire chain from the introduction of innovative products, transportation, distribution, to product quality supervision and supply chain services. Together, we will promote the optimization of the policy environment and explore more innovative cooperation models."

Huo Peiqiong, General Manager of China Resources Pharmaceutical Commercial South China Region and China Resources Guangdong Pharmaceutical, stated: "China Resources Guangdong Pharmaceutical, based in the Greater Bay Area, as a national team and main force in the pharmaceutical distribution industry, grasps the trend of economic globalization development and is committed to building a trusted social and leading health ecosystem service platform for industry advancement. Through this signing, China Resources Guangdong Pharmaceutical will leverage its international supply chain advantages, and through resource sharing, complementary strengths, and business innovation, seize innovative development opportunities with Teva to jointly provide patients with higher quality and more comprehensive products, driving both parties' businesses to achieve leapfrog development."

At the 6th CIIE, Teva, as a "returning customer," will once again showcase several star products covering multiple fields. Among them is the innovative migraine drug Fremanezumab, which will make its China debut, and Sudocream, the first over-the-counter health consumer product in China, to meet the growing and diverse health consumption needs of the Chinese people. Additionally, the results of the 5th CIIE, including the product Copaxone,^®, Innovative Drug Antates^®Ji Cun Da^®will also make an appearance, with a more comprehensive and diversified business layout to benefit the Chinese people, continuing the "In China, For China" chapter of health.